Literature DB >> 11587046

The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes.

H Keen1, E T Lee, D Russell, E Miki, P H Bennett, M Lu.   

Abstract

AIMS/HYPOTHESIS: We aimed to estimate incidences of any retinopathy and proliferative diabetic retinopathy (PDR) by direct ophthalmoscopy and relate them to baseline risk factors in re-examined diabetic survivors from 10 centres of the WHO Multinational Study of Vascular Disease in Diabetes.
METHODS: After a mean follow-up of 8.4years (11.7 years in Oklahoma), 2877 (71.6%) survivors were resubmitted to standardised direct ophthalmoscopy as at baseline. The presence of any retinopathy and PDR were recorded at each centre and their incidence estimated in those without retinopathy and PDR at baseline. The independent associations of these incidences with baseline risk factors are expressed as odds ratios derived from multiple logistic regression analyses, within individual centres (which included fasting plasma glucose in 8 and triglyceride in 5) and in pooled data.
RESULTS: Of the 4662 original patients, 465 (10.4%) of those without and 77 (43.0%) of those with baseline PDR had died (p < 0.001). Any retinopathy was newly reported at follow-up in 47.7 % and PDR in 9.7 % of those free of them at baseline, with reported incidences varying substantially among centres. Incident retinopathy appeared earlier in the known course of diabetes but incidence rates rose more slowly with duration in patients with Type II (non-insulin-dependent) diabetes mellitus than in those with Type I (insulin-dependent) diabetes mellitus. In pooled data and in some individual centres, any retinopathy incidence gave significantly positive odds ratios with age, diabetes duration, systolic pressure, plasma cholesterol, BMI, insulin treatment and proteinuria, and with fasting plasma glucose in the centres where it was measured. Positive odds ratios for PDR were similarly obtained for age, duration, insulin treatment, cholesterol, proteinuria and fasting glycaemia. Smoking status odds ratios were negative for both outcomes. CONCLUSION/
INTERPRETATION: Incidence of ophthalmoscopically ascertained any retinopathy varied about twofold and of PDR about threefold among centres. Although, in part attributable to differences between observers, variation in incidence in all centres and in some cases within centres was associated with a number of baseline risk factors. Such associations are not likely due to observer variation or selection biases and emerged despite the imprecision of clinical ophthalmoscopy. Improved detection and control of these risk factors should reduce the impact of diabetic retinopathy and its consequences.

Entities:  

Mesh:

Year:  2001        PMID: 11587046     DOI: 10.1007/pl00002935

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients.

Authors:  H P Hammes; W Kerner; S Hofer; O Kordonouri; K Raile; R W Holl
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

Review 2.  The prevalence of retinopathy among type 2 diabetic patients in Iran: A systematic review and meta-analysis.

Authors:  Masoud Mohammadi; Ali Akbar Vaisi Raiegani; Rostam Jalali; Akram Ghobadi; Nader Salari
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 3.  Blood pressure control for diabetic retinopathy.

Authors:  Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank
Journal:  Cochrane Database Syst Rev       Date:  2015-01-31

4.  Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy.

Authors:  B O Boehm; G Lang; O Volpert; P M Jehle; A Kurkhaus; S Rosinger; G K Lang; N Bouck
Journal:  Diabetologia       Date:  2003-03-01       Impact factor: 10.122

5.  Six-year retrospective follow-up study of safe screening intervals for sight-threatening retinopathy in patients with diabetes mellitus.

Authors:  Enrique Soto-Pedre; Maria Concepcion Hernaez-Ortega; José Antonio Vázquez
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

6.  [Diabetic retinopathy and maculopathy].

Authors:  H-P Hammes
Journal:  Internist (Berl)       Date:  2011-05       Impact factor: 0.743

7.  Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial.

Authors:  Piero Ruggenenti; Ilian Iliev; Marco Filipponi; Stefano Tadini; Annalisa Perna; Maria Ganeva; Bogdan Ene-Iordache; Paolo Cravedi; Roberto Trevisan; Antonio Bossi; Giuseppe Remuzzi
Journal:  J Ophthalmol       Date:  2010-06-10       Impact factor: 1.909

8.  BglII gene polymorphism of the alpha2beta1 integrin gene is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes.

Authors:  Mojca Globočnik Petrovič; Marko Hawlina; Borut Peterlin; Daniel Petrovič
Journal:  J Hum Genet       Date:  2003-08-23       Impact factor: 3.172

9.  A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes.

Authors:  Borut Peterlin; Mojca Globočnik Petrovič; Jana Makuc; Marko Hawlina; Daniel Petrovič
Journal:  J Hum Genet       Date:  2003-11-15       Impact factor: 3.172

10.  Increased serum periostin concentrations are associated with the presence of diabetic retinopathy in patients with type 2 diabetes mellitus.

Authors:  Y Ding; Q Ge; H Qu; Z Feng; J Long; Q Wei; Q Zhou; R Wu; L Yao; H Deng
Journal:  J Endocrinol Invest       Date:  2018-01-18       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.